Japan's Ministry of Health, Labour and Welfare has officially approved a subcutaneous injection version of lecanemab, an Alzheimer's disease treatment drug, allowing patients to self-administer the medication at home. The approval, granted on September 16, 2026, marks a significant shift in dementia care accessibility for patients across Japan, including the country's foreign resident population. According to NHK, the new subcutaneous injection format eliminates the need for patients to visit medical facilities regularly for intravenous infusions, which has been the standard administration method since the drug's initial approval. This development is expected to substantially reduce the burden on patients and their caregivers, who previously had to arrange frequent hospital visits for treatment. Lecanemab, developed by pharmaceutical company Eisai, is designed to slow cognitive decline in patients with early-stage Alzheimer's disease by targeting amyloid-beta proteins in the brain. The drug gained attention worldwide as one of the first treatments to demonstrate meaningful clinical benefits in slowing disease progression, rather than merely addressing symptoms. The shift from intravenous to subcutaneous administration represents a major advancement in treatment convenience. Intravenous infusions typically require patients to spend several hours at a medical facility every two weeks, including travel time, waiting periods, and the infusion itself. For elderly patients with mobility challenges or those living in rural areas with limited access to specialized medical centers, these regular visits can pose significant logistical and physical difficulties. For foreign residents in Japan, this approval brings both opportunities and considerations. Expats caring for elderly family members or those personally affected by Alzheimer's disease should be aware that while self-administration at home is now possible, proper training and medical guidance will be essential. Patients and caregivers will need to work closely with their healthcare providers to ensure correct injection techniques and monitor for potential side effects. The subcutaneous version maintains the same therapeutic benefits as the intravenous formulation while offering greater flexibility in treatment scheduling. Patients who are comfortable with self-injection or have family members who can assist may find this option particularly appealing. However, it's important to note that not all patients will be suitable candidates for at-home administration, and healthcare providers will make individual assessments based on each patient's circumstances. Language barriers may present additional challenges for non-Japanese speaking expats navigating this new treatment option. Foreign residents should ensure they have access to medical interpretation services or bilingual healthcare providers who can explain proper injection procedures, storage requirements, and warning signs of adverse reactions. Many international hospitals and clinics in major Japanese cities offer services in English and other languages, which may be particularly valuable when learning self-administration techniques. The approval also reflects Japan's broader efforts to reduce healthcare system strain while improving patient quality of life. As the country grapples with a rapidly aging population and increasing dementia cases, home-based treatment options help alleviate pressure on medical facilities while empowering patients to maintain greater independence. Expats interested in this treatment option should consult with their neurologists or primary care physicians to determine eligibility. Japan's national health insurance system typically covers approved Alzheimer's treatments, though patients should verify coverage details and any out-of-pocket costs with their insurance providers. This development positions Japan at the forefront of accessible dementia care, offering hope to the estimated six million people in the country living with dementia and their families. For the expatriate community, staying informed about such healthcare innovations ensures access to the best possible medical care while residing in Japan.